Article Information
History
- January 19, 2022.
Article Versions
- Version 1 (January 10, 2022 - 01:42).
- Version 2 (January 10, 2022 - 15:42).
- Version 3 (January 12, 2022 - 15:06).
- You are viewing Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- John Schrom1,
- Carina Marquez1,
- Genay Pilarowski2,
- Grace Wang3,
- Anthea Mitchell3,
- Robert Puccinelli4,
- Doug Black1,
- Susana Rojas2,
- Salustiano Ribeiro2,
- Jacqueline Martinez2,
- Diane Jones2,
- Robert Nakamura5,
- Vivek Jain1,
- Maya Petersen4,
- Joe DeRisi3,* and
- Diane Havlir1,*,#
- 1University of California, San Francisco, CA
- 2Unidos en Salud, San Francisco, CA
- 3Chan-Zuckerberg Biohub, San Francisco, CA
- 4University of California, Berkeley, CA
- 5California Department of Public Health, CA
- ↵# Corresponding author; email: diane.havlir{at}ucsf.edu
↵* Authors contributed equally
Posted January 19, 2022.
Direct Comparison of SARS-CoV-2 Nasal RT-PCR and Rapid Antigen Test (BinaxNOW™) at a Community Testing Site During an Omicron Surge
